Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.
From the U.S. FDA-approved label for Naloxone. Full label: DailyMed.
Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care.
From the U.S. FDA-approved label for Naloxone. Full label: DailyMed.
Naloxone HCl Nasal Spray is for intranasal use only., Seek emergency medical care immediately after use., Administration of a single spray of Naloxone HCl Nasal Spray intranasally into one nostril., Administer additional doses of Naloxone HCl Nasal Spray, using a new nasal spray with each dose, if the patient does not respond or responds and then relapses into respiratory depression, additional doses of Naloxone HCl Nasal Spray may be given every 2 to 3 minutes until emergency medical assistance arrives., Additional supportive and/or resuscitative measures may be helpful while awaiting emergency medical assistance.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Naloxone HCl Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients. Hypersensitivity to naloxone hydrochloride.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance., Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following serious adverse reactions are discussed elsewhere in the labeling: Precipitation of Severe Opioid Withdrawal Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
5 products from 3 makers in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Nalox 400mcg Injection | Naloxone (400mcg) | Samarth Life Sciences Pvt Ltd | vial of 1 ml Injection |
| Narcotan 20mcg Injection | Naloxone (20mcg) | Troikaa Pharmaceuticals Ltd | vial of 2 ml Injection |
| Narcotan 400mcg Injection | Naloxone (400mcg) | Troikaa Pharmaceuticals Ltd | vial of 1 ml Injection |
| Narcotan 40mcg Injection | Naloxone (40mcg) | Troikaa Pharmaceuticals Ltd | vial of 2 ml Injection |
| Nex 400mcg Injection | Naloxone (400mcg) | Neon Laboratories Ltd | vial of 1 ml Injection |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
